medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2006, Number 3

<< Back Next >>

Rev Biomed 2006; 17 (3)

Management of the acute migraine episode with sumatriptan vs. metoclopramide

Salazar-Zúńiga A, Garfias-Arvizu A

Language: English
References: 38
Page: 175-182
PDF size: 197.25 Kb.


ABSTRACT

Background. The pathophysiology of migraine remains unclear but the development of more specific drugs against migraine has revealed new insights into the structures and mechanisms involved. The efficacy of these new drugs varies among patients. In this study we assessed the efficacy of metoclopramide in comparison with sumatriptan to alleviate the acute phase of migraine.
Hypothesis. Metoclopramide is more effective than sumatriptan as migraine abortive therapy.
Methods. One hundred and twenty patients ranging from 18 to 65 years of age were divided at random into two groups. One group received 10 mg of metoclopramide (IV, three min), and the other group 6 mg of sumatriptan (subcutaneously, slowly). We registered the time course of pain decrease and the main secondary effects. Data were analyzed by X2 with a significance level of P‹0.01.
Results. The use of metoclopramide reduced the headache from level 3 to levels 0 or 1 in the first 15 min in 70% of the cases, while sumatriptan reduced the headache in only 58% of the patients. The autonomic symptoms associated with migraine (nausea and vomiting) respond better to metoclopramide. Furthermore, it has less secondary effects than sumatriptan.
Conclusions. In this study metoclopramide was more effective in alleviating the acute phase of migraine, and had less secondary effects than sumatriptan.


REFERENCES

  1. 1.- Goadsby PJ,, Lipton RB, Ferrari MD. Migraine current understanding & treatment. N Engl J Med 2002; 346:257-70.

  2. 2.- Leao AAP. Spreading depression of activity in the cerebral cortex. J NeuroPhysiol 1944; 7:359-90.

  3. 3.- Olesen J, Larsen B, Lauritzen M. focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981; 9:344-52.

  4. 4.- Hadjikhani N, Sánchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001; 98:4687-92.

  5. 5.- Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87:543-52.

  6. 6.- Dvorkin GS, Andermann F, Carpenter S, et al. Classical migraine, intractable epilepsy and multiple strokes: a syndrome related to mitochondrial encephalomyopathy. In: Andermann F, Lugaresi E, eds: Migraine and epilepsy. Boston: Butterworth. & Co 1987:203-32.

  7. 7.- Welch KM, Ramadan NM. Mitochondria, magnesium and migraine. J Neurol Sci 1995;134:9-14.

  8. 8.- Codignola A, Tarroni P, Clementi F, Pollo A, Lovallo M, Carbone E, Sher E. Calcium channel subtypes controlling serotonin release from human small cell lung carcinoma cell lines. J Biol Chem 1993; 268:26240-7.

  9. 9.- Welch KM. Drug therapy of migraine. N Engl J Med 1993; 329:1476-83.

  10. 10.- Coppola M, Vealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995; 26:541-6.

  11. 11.- Schwarzberg MN. Application of metoclopramide specificity in migraine attacks therapy. Headache 1994; 34:439-41.

  12. 12.- Ellis GL, Delaney J, Dehart DA, Owens SA. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993; 191-5.

  13. 13.- Esteban-Morales A, Trujillo Chavez P, Rivera-Martínez G Salazar-Zúńiga A. Clinical response of metoclopramide vs sumatriptan in the treatment of acute migraine attack (preliminary study). Revista de Sanidad Militar México 1999; 53:36-40.

  14. 14.- Veliskova J, Claudio OI, Galanopoulouas, Kyrozis A, Lado FA, Ravizza T, et al. Development aspects of basal ganglia and therapeutic perspectives. Epileptic Disord 2002; 4(suppl 3):S73-S82.

  15. 15.- Ottman R, Lipton RB. Comorbidity of migraine and epilepsy. Neurology 1994; 44:2105-10.

  16. 16.- Moshe SL. Epileptogenesis and the immature brain. Epilepsia 1987; 28 (suppl 1):S3-S15.

  17. 17.- Schoenen J. Acute migraine therapy: the newer drugs. Curr Opin Neurol 1997; 10:237-43.

  18. 18.- Olesen J, Lipton RB. Headache classification update Curr Opin Neurol 2004; 17(3) 275-82.

  19. 19.- Saper JR. Diagnosis and symptomatic treatment of migraine. Headache 1997; 37(suppl1):S1-S13.

  20. 20.- Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31:291.

  21. 21.- The subcutaneus sumatriptan International study group. Treatment of migraine attack with sumatriptan. N Engl J Med 1991; 325:316-21.

  22. 22.- Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology 1994; 44(suppl4):S17-S23.

  23. 23.- Friedman PA. Headache. In: Baker AB, ed. Clinical Neurology. Philadelphia, Pa: Harper & Row; 1987: 1-50.

  24. 24.- Akpunonu BE, Mutgi AB, Federman DJ, Volinsky FG, Brickman K, Davis RL, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency room department: a multicenter study. Ann Emerg Med 1995; 25:464-9.

  25. 25.- Bigal MZ, Bordini CA, Speciali JG. Intravenous chlorpromazibe in the emergency department treatment of migraines: A randomized controlled trial. J Emerg Med 2002; 23;141-8.

  26. 26.- Meredith JT, Wait S, Brewer KL. A prospective double blind study of nasal sumatriptan vs Ketorolac in migraine headache. Am J Emerg Med 2003; 21:173-5.

  27. 27.- Krymchamtowsky AV, Barbosa JS. Dexamethasone decrease migraine recurrence observed after treatment with a tryptan combined with nonsteroidal antiinflamatory drug. Arq Neuropsiquiatr 2001; 59:708-11.

  28. 28.- Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT 1B/1D agonists: Insights into migraine pathophysiology using rizatriptan. Neurology 2000; 55(suppl 2):S8-S14.

  29. 29.- Larson BT, Samford MD, Camdem JM, Piper EL, Kerley MS, Paterson JA & Turner JT. Ergovaline binding and activation of D2 dopamine receptors in GH4ZR7 cell. J Anim Sci 1995; 73:1396-400.

  30. 30.- Bruton LL. Agents affecting gastrointestinal water flux and motility; emesis and antiemetics; bile acids and pancreatic enzymes In: Goodman AG, Rall TW, Nies AS, Taylor P, eds. The pharmacological basis of therapeutics. 9eth ed.; Mc Graw-Hill NY. 1996: 917-36.

  31. 31.- Fozzard JR & Mobarok Ali AT. Blockade of neural tryptamine receptors by metoclopramide. Eur J Pharamacol 1978; 49:109-12.

  32. 32.- Walkenbach J, Brüss M, Urban WB, Barann M. interactions of metoclopramide and ergotamine with human 5-HT3A receptors and human 5-HT reuptake carriers. BJP 2005;1-10.

  33. 33.- Fischtl B, Fulgraff G, Neumann H G, Wollenberg P, Forth W, et al. Algemeine pharmakologic und toikologie. In: Allgemeine und spezielle pharmakologie und toxikologie, ed. Forth W, Henschler D, Rummel W, & Starke K. 7th ed pp 3-102. Heidelberg Specktrum akademischer Verlag.

  34. 34.- Goldstein DJ, Roon KI, Offen WW. Et al. Selective serotonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomized controlled trial. Lancet 2001; 358:1230-4.

  35. 35.- Visser WH. 5-HT, Receptor antagonist in the acute treatment of migraine. Clinical, epidemiological, and pharmacological aspects. Delft, The Netherlands Eburon-Delft; 1996.

  36. 36.- Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. Headache 1996; 36:329-31.

  37. 37.- Sandrini G, Färkkilä M, Burgess G, Forstner E, Haughie S. Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002;59:1210-7.

  38. 38.- Berkovitch M, et al. The safety of metoclopramide for nausea and vomiting of pregnancy: A prospective multicentre international study (Manuscript in preparation).




2020     |     www.medigraphic.com